US$ 20.54
fda warning letters compounded semaglutide 2025 Issues Warnings Against Illegal GLP-1 Marketing FDA Targets GLP-1 and Peptide
Description
The medication is FDA-approved (Mounjaro) for improving glycemic control in adults with type 2 diabetes and may also be prescribed for chronic weight management under FDA review and specific eligibility criteria

Diabet Obes Metab 20:6068

doi: 10.1038/aps.2011.168 40

Some plans cover these medications with prior authorization demonstrating medical necessity

Verzending binnen Nederland & levertijden LeoLabShop vermeldt dat ze samenwerken met DHL voor levering

Some people who take semaglutide report having chest discomfort